SCHEMBL6006466

SCHEMBL6006466

CCOC(=O)CCCCCN[C]=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
GAA P10253 2/20 0.47
EPHX2 P34913 2/20 0.47
ALDH1A1 P00352 3/20 0.46
ALOX15 P16050 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NAMPT P43490 1/20 0.45
DGKA P23743 1/20 0.44
KMT2A Q03164 2/20 0.44
MGAM O43451 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
USP2 O75604 1/20 0.41
PAM P19021 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
NR1I2 O75469 1/20 0.40
PGR P06401 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8176275 0.98 CYP1A2 (0.50) CYP1A2GAAEPHX2ALDH1A1ALOX15
SCHEMBL5651628 0.93 CYP1A2 (0.52) CYP1A2GAAEPHX2ALDH1A1ALOX15
SCHEMBL9099953 0.86 DGKA (0.55) EPHX2ALDH1A1TSHRDGKAUSP2
SCHEMBL1938228 0.85 GAA (0.50) CYP1A2GAAALDH1A1TSHRKMT2A
SCHEMBL6006524 0.85 DGKA (0.58) EPHX2ALDH1A1TSHRDGKAPAM
SCHEMBL11790090 0.84 CYP1A2 (0.47) CYP1A2GAAEPHX2ALDH1A1ALOX15
SCHEMBL7488981 0.83 DGKA (0.61) EPHX2TSHRDGKAPAML3MBTL1
SCHEMBL7003583 0.83 TSHR (0.54) GAAEPHX2ALDH1A1TSHRHSD17B10
SCHEMBL222756 0.83 TSHR (0.54) GAAEPHX2ALDH1A1TSHRHSD17B10
SCHEMBL10451703 0.81 DGKA (0.37) GAAEPHX2ALDH1A1TSHRNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 CYP1A2 68/4885GAA 2117/4885EPHX2 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.